Treatment

PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion clinical trials

2 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
This study is looking at a new treatment called lifileucel for people with advanced melanoma that has already been treated. It's an early-stage study to see how well the treatment works and if it's safe. It uses your own immune cells to fight the cancer.
For: Previously treated advanced melanoma
France · Italy · Germany
Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors (EVICTION-2)
This study is testing new ways to treat advanced cancers like prostate, bowel, and skin cancer. It looks at the safety and how well a new drug, ICT01, works when given with another medicine, Proleukin, for people whose cancer has spread.
For: metastatic castration-resistant prostate cancer (mCRPC) · metastatic colorectal cancer (CRC) · metastatic pancreatic ductal adenocarcinoma (PDAC)
France · Germany